||EPS - Basic
||Market Cap (m)
Real-Time news about Micap (London Stock Exchange): 0 recent articles
|memoeryman: dell314 - 10 May'06 - 11:53 - 48 of 67
FROM THE EEG THREAD......for posting inacrurate and deliberetley reramping the share price with false info ...IMHO DYOR
Post removed by ADVFN
dell314 - 10 May'06 - 12:40 - 53 of 67
Post removed by ADVFN
dell314 - 10 May'06 - 12:59 - 56 of 67
Post removed by ADVFN|
|m.t.glass: "..Evershed monitors the share price of
a large number of companies and will buy
shares in companies he likes when they
are very depressed.." (Shmag, April 2004)
"...I'm absolutely stuffed with technology at
the moment it makes up 30% of the portfolio.
The uplift's absolutely enormous if you get the
right ones..." (MoneyWeek interview, Nov 2005)|
|sharedoc: If and when the news does come, the share price will go whooooooosh|
|matthu: Some people get scared out of their holdings by looking at the downward trend of the share price - this is a share that will only really appreciate once it turns profitable.
Having said that, most of the sales seem to have been for only a couple of £k each, so maybe people are selling to cover Christmas expenses, or selling to pay tax bills or simply to reinvest in an ISA. Or perhaps they set themselves a stop loss when they bought in?|
|gjabrj: Where is the share price heading???|
Still here too--cannot understand this share price being so low.....
|beckaroo: Mintyfool, Another question on the convertibles. If MICAP gets taken over before they expire what happens to the convertibles?? Also I see they rose to 20p at start of March (following share price rise to 80p) but didn't fall down again till share price was below 50p in the middle of May.
|10km: A few notes on Micap when I started researching them a few months go .Probably been covered earlier on this thread .
Good long term potential here me thinks
MICAP June 2004 Micap .Another encapsulation company that might be worth keeping an eye out for.
Micap floated on AIM in August 2003 through a successful placing at 55p per share. (price now 48p to buy) raising more than £5m .
Annual losses slashed by more than £3 m
Losses to March 31 were £650,000 down from £3..9 m
Turnover increased from £90,000 to £900,000
May global commercial launch of its encapsulated flavour products by its licensee Fimtech, worlds largest privately owned flavour & fragrance company
(global flavourings market estimated at £4bn)
Micap's technology holds flavour in using yeast cells , only releasing it when it hits the tongue.
It can Also be used for more effective delivery of pharmaceuticals and pesticides
Micap has been split into three divisions .
1) Micap Flavours ?
2) Micap Healthcare
3) Micap Specialities
Deals with Firmtech
Agreements with a U.K manufacture of oriental products ?
SkyPharma is the largest shareholder with 35%. With Sigma Venture Funds also l holding a significant amount.|
|beckaroo: I see that Micap have the MRSA stuff in their August newsletter, via their website. All looks good promising stuff and the microencapsulated essential oil stuff looks applicable to many other areas.
Also, This is from the SkyePharma board (thanks to AceUK), via Citywire:-
First step for Micap and Skyepharma fails to excite
Published: 11:36 Tue 17 Aug 2004
By Graeme Davies, Companies Correspondent
Drug delivery specialist Skyepharma has chosen the first of a potential ten products to use the microencapsulation technology developed by Citywire tip Micap but the news has failed to budge the share price of either stock by much.
The announcement brings the first crystallisation of a deal signed between the two companies in March which allows Skyepharma to use Micap's technology in up to ten products. The initial deal paid Micap £500,000 with further payments to come as products enter clinical trials and royalties will follow.
Micap's shares (MIC) have added 0.5p to 44p this morning but Skyepharma's (SKP) are up 0.25p at 52.5p, just off their 2004 low of 50p. The link up between the two companies began last year when Skyepharma made a £2 million investment in Micap and Skyepharma founder Ian Gowrie-Smith became Micap's non-executive chairman.
Frankly it would have been a bigger surprise to investors had Skyepharma not actually taken up Micap's technology for development within its own drug delivery systems, hence the rather lacklustre response from the market this morning. The true worth of the deal between the companies will only be seen when products start to progress through trials.
Perhaps the reaction from investors would have been more enthusiastic had the companies deigned to tell us which product has been chosen but it has not been disclosed 'for reasons of commercial confidentiality.'
Pharmaceutical developments are the third string to Micap's bow as it is already pushing its technology for use in food and herbicide applications. This technology involves the encapsulation of active ingredients in yeast cells which allows for selective release and protection from high temperatures and UV light.
Citywire tipped Micap at 52.5p in January and as the vogue for small cap investment continued into the spring it rose as high as 83p but recently it has slipped back below the level at which we rated it a 'risky buy.' However we remain confident its bespoke technology will find its niche in the market and such investments are always likely to be choppy and to take some time to come to fruition.
Skyepharma has been the perfect illustration of how uncertain conditions can be when investing in blue sky pharmaceutical companies. Its share price has fluctuated between 41.5p and 79p over the past 18 months as first the company made a maiden profit then slipped back into losses last year after failing to sign licensing deals before the end of the year.
Both companies retain great potential and Skyepharma expects more products to hit the market this year. Newsflow is always important in supporting such companies' share prices and both will be hoping to report further progress from their tie-up throughout the coming months.
see my earlier post no 52 for SIGMA's shareholding including CLS.
I am confident if MICAP continues to be managed prudently its only at the early stages of what could be a steady increase in share price. Todays move was par for the course after such a strong day yesterday in fact it held up better than I had expected in view of the inevitable profit taking .
I hold both SIGMA and MICAP and I think as MICAP begins to get more press exposure SIGMA will increasingly be seen as a second Prelude Trust (PDT) and shareholders in MICAP and SIGMA will then be in a virtuous circle one feeding on the others exposure alternately - its amazing how this sort of momentum can build up .
If you look at the PDT thread its very active . The share price of PDT has gathered momentum on the back of speculation with regard to the progress and real value of the underlying investments ,most of which are early stage.
unquoted companies .|
Micap share price data is direct from the London Stock Exchange